Episodi
-
This podcast speaks with experts from Altmetric to delve into different methods for extracting insights to comprehend the influence of a publication on key metrics such as citations, public engagement, social impact, and internal metrics. The aim is to speed up the evaluation process to determine if publications are effectively reaching and educating the appropriate HCPs to influence their clinical decisions.
-
This session takes a closer look at one of the key challenges associated with integrated evidence generation planning that was identified in our first installment. Experts share insights and practical advice on ways to identify and overcome barriers to aligning multiple functions in the development and implementation of integrated evidence generation plans to minimize risk and optimize value, accounting for medical affairs, patient, regulatory and commercial perspectives.
-
Episodi mancanti?
-
Recorded at the MAPS 2024 Annual Meeting in Puerto Rico following a workshop on modular content in which all of today’s speakers were faculty.
Lead by the Digital FAWG’s Jennifer Riggins and Steve Casey, today’s panelists touch on the topic of modular content in the following areas:
Inspiration and ImpactContent Compliance & ApprovalMSL UtilizationTraining & EvolutionThe Technology StackThe Future of Modular ContentFor more information on Modular Content, explore the MAPS White Paper: “Modular Content in Medical Affairs: The Foundation of Omnichannel Engagement” HERE: https://medicalaffairs.org/modular-content-omnichannel-engagement/
-
As the sources of data and technologies needed to make sense of data expand, opportunities exist for further integrating Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) alongside traditional approaches when planning data generation activities to support new product registration, access, and use. Here we speak with experts from Lumanity about the Integrated Evidence Generation Planning (IEGP) process and how to overcome the barriers to success.
-
Here we speak with Kate Davies, Nurse Educator at London South Bank University and expert in clinical endocrine research focusing on genetics in short stature, clinical trials, and differences in sex development. Throughout Kate's research and work as a pediatric nurse, she has developed expertise in engaging with patient communities, often providing trusted information to these groups and also learning about the real-world experiences of patients in the context of treatment and clinical trials. Here is what a patient advocate wants Medical Affairs to know about patient engagement -- and join us at our LinkedIn discussion on this topic to ask your own questions about engaging with patients.
-
Getting the most impact from a publication requires being able to define who the audience is and how to reach them, across both journals and online channels, especially in complex/niche cases. In this podcast, we’ll discuss the benefits of taking an analytical approach.
-
When you think about innovation in Medical Affairs, perhaps the first things that come to mind are GenAI or maybe new approaches to KOL network mapping. But what about innovation in the ways we approach the profession itself? What about innovation in how we continue to evolve our own skills and understanding of our roles in industry and beyond? Here we speak with Tim Mikelhashvili, CEO of Amedea Pharma about innovation in Medical Affairs leadership -- and innovation for leaders. We also look forward to Tim's 2024 Medical Affairs Innovation Olympics. Enter your innovative idea now or register to attend!
-
A PubMed search on the day this was written finds 36,735 new publications in the last 24 hours. Adding the word “oncology” narrows the number to 4,334. Substituting “lung cancer” for “oncology” results in 534 articles. How many of these do you think your HCPs and KOLs will be able to read before the next batch of publications comes out tomorrow? This is to say that publishing a scientific study or article can feel like squeezing an eyedropper into the ocean and it is the job of the publication’s team to ensure this drop-in-the-ocean has impact — especially when publishing a study with the potential to change clinical practice. Here we learn practical tips straight from the source – namely, experts at Wiley. How can you translate peer-reviewed publications to clinical impact? How can licensing extend (or perhaps restrict…) the reach of published research? How can publications be leveraged as the hub of an omnichannel approach? Listen to learn more.
-
Is there a correlation between a higher journal impact factor and increased reach and engagement? The answer has always been, "Of course!" But now with companies driving their own engagement, and alternatives to the journals becoming more mainstream and accepted everyday, the answer is more nuanced. Join our expert guests from Digital Science to discuss the NEW metrics of journal publication.
-
When Medical Affairs was a support function, it was enough to count the actions we performed to aid the missions of our collaborators in Commercial and R&D. Now that Medical is a strategic partner alongside these other functions, we must measure and message our OWN mission. But how can we draw a line of causality or at least contribution from actions to impact? Here we speak with Diana Morgenstern, MD, Fellow of the American College of Physicians, member of the MAPS EvGen Domain Team, and Executive Strategist in the IQVIA US Medical Affairs Center of Excellence, and Javier Lopez-Molina, MBA, Senior Director of in the US Medical Affairs Center of Excellence, IQVIA about exactly this challenge. And we ask a very important question: now that we appreciate the need to demonstrate impact and technologies exist that allow us to measure impact...what's holding us back?
-
As Medical Affairs professionals, many of us have moved from first careers in academia or healthcare. What did your colleagues say when you told them you were transitioning to pharma? Did they say you were going to the "dark side"? In this episode, we speak with Robert Atkinson, President of the Information Technology and Innovation Foundation and author of the recently published book, Technology Fears and Scapegoats: 40 Myths About Privacy, Jobs, AI, and Today’s Innovation Economy. And we explore the origins of negative opinions of the pharmaceutical industry, and whether a for-profit model can support both innovation and the society's best interests.
-
Modern scientific storytelling is about more than data dissemination — it's about creating meaning for the audience, and as such (as any good bard on the stool of a Medieval tavern knows) it requires truly understanding the audience's motivations and needs. However, scientific storytelling goes further. Our goals are not fiction nor purely entertainment — it's helping HCPs and KOLs make patients lives better. Here we talk about this approach with Murali Gopal, Vice President and Head of Medical Affairs at Phathom Pharmaceuticals and Dave Gulezian, co-Founder and CEO at Alucio. And we ask what is the ONE thing a company must implement in their transformation from the 40-slide deck to modern scientific storytelling. Spoiler alert: They actually agree and it's something that doesn't require budget.
-
We know the expectations of our job and we likely know the purpose of our organization. But what is the purpose of your role? What is the golden thread that guides your work? Does it connect to your personal purpose, your organization's purpose or both? Here we speak with Jill Donahue, author of the recently published (free!) book, "A Dose of Inspiration: 100 Purpose Stories from Pharma Leaders" about the individual and organizational benefits of discovering your purpose as an employee in the Life Sciences industry — as well as previewing some of the purpose stories Jill uncovered while writing the book.
Links:A Dose of Inspiration: 100 Purpose Stories from Pharma Leaders
Article: Tired of Being Told You Went to the Dark Side?
-
Continuing Medical Education (CME) is transitioning from in-person, day-long seminars to bite-sized, virtual, learn-at-your-own pace courses. Here we talk with experts from Wiley and the world of consulting about new directions in CME — and how to address the continuing need for social learning and perceived authority even as we make information more consumable.
-
Many of us think about machine learning and AI as a way for an audience to get information: We ask ChatGPT a question and it provides the answer. Here we explore machine learning as a way to get information about an audience — both audience segments/personas and individuals within these groups. We also discuss the limitations and data privacy concerns that distinguish what we "could" know from what we "should" discover. And it turns out machine learning is not just a tool for mining he external environment, but also a way to make sense of a company's internal data to discover hidden experts and resources within the company.
-
In our last podcast episode of this series, we talked with Matt Lewis. We discussed generative AI, what it is and how it may change and evolve the medical communications environment. Today, we dive into a really important area that can significantly influence your GenAI results - Prompt Engineering and other areas.
-
In this podcast, we delve into the world of omnichannel strategies in Medical Affairs, where understanding your audience's educational needs and communication preferences is pivotal for delivering relevant and engaging data dissemination.
Join us as we explore how to develop effective communications by leveraging various sources of audience understanding, and how to translate information into actionable insights.
Discuss what the gold standard for insights could look like and highlight practical suggestions for how to yield robust insights while navigating common challenges often associated with using insights.
This podcast provides an overview into the multifaceted process of understanding your audience and explains the complexities and opportunities within the Medical Affairs space to ensure that your communications resonate with your audience, and ultimately, support their educational goals.
-
In Medical Affairs, our eyes are open to the vast possibilities of Artificial Intelligence — not only to make our current work more efficient, but to expand our capabilities in areas we never considered possible. Here, MAPS speaks with experts from Pfizer and Putnam Associates about the most exciting current uses of AI and also where we may be headed in the future. Join us for a wild ride through the possibilities of AI.
-
MAPS speaks with Liz de Somer, CEO of Medicines Australia and Sharon Winton, CEO of Lymphoma Australia to explore patient engagement from the perspectives of industry and patient associations. Liz and Sharon are also speaking about this topic at the MAPA/MAPS Medical Affairs Summit in Sydney, AU, Nov 8-10, 2023.
- Mostra di più
